Desjardins Global Asset Management Inc. Has $126,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Desjardins Global Asset Management Inc. trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 36.3% during the fourth quarter, Holdings Channel reports. The firm owned 1,658 shares of the medical research company’s stock after selling 946 shares during the period. Desjardins Global Asset Management Inc.’s holdings in Edwards Lifesciences were worth $126,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. United Asset Strategies Inc. boosted its holdings in Edwards Lifesciences by 14.3% during the fourth quarter. United Asset Strategies Inc. now owns 9,123 shares of the medical research company’s stock valued at $696,000 after purchasing an additional 1,142 shares in the last quarter. SVB Wealth LLC raised its stake in shares of Edwards Lifesciences by 23.4% in the fourth quarter. SVB Wealth LLC now owns 6,059 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 1,150 shares during the last quarter. Invesco LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $339,000. Cullen Investment Group LTD. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $1,379,000. Finally, Carnegie Capital Asset Management LLC raised its stake in shares of Edwards Lifesciences by 12.4% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 6,370 shares of the medical research company’s stock valued at $486,000 after acquiring an additional 701 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EW. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research report on Friday, February 2nd. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $85.94 on Friday. The firm has a fifty day moving average of $90.15 and a two-hundred day moving average of $78.31. The stock has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 4.32 and a beta of 1.05. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the previous year, the business earned $0.64 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock valued at $17,166,254 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.